Bevacimab 400 mg/16 ml (IV Infusion)
400 mg vial: ৳ 58,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Bevacizumab |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- Metastatic colorectal cancer treatment
- Non-squamous non-small cell lung cancer treatment
- Glioblastoma treatment
- Metastatic renal cell carcinoma treatment
- Cervical cancer treatment
- Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment
Pharmacology
- Recombinant humanized monoclonal IgG1 antibody
- Binds to and inhibits the biologic activity of vascular endothelial growth factor (VEGF)
- Approximate molecular weight of 149 kD
- Produced in a mammalian cell (Chinese Hamster Ovary) expression system
Dosage
- Treatment until disease progression or unacceptable toxicity
- Recommended doses for different types of cancer
- Specific recommended doses for different chemotherapy regimens
Administration
- Do not administer as an IV push or bolus
- Preparation for administration
- First infusion duration
- Subsequent infusion duration
- Use of appropriate aseptic technique
- Visual inspection prior to administration
- Necessary amount withdrawal and dilution
- Discard unused portion
Interaction
- Study demonstrating no significant effect of Bevacimab on the pharmacokinetics of irinotecan
Contraindications
- No contraindications listed in the manufacturer’s labeling
Side Effects
- Common adverse reactions
- Incidence and rates
Pregnancy & Lactation
- Potential fetal harm based on findings from animal studies
- No data available on bevacizumab in human milk
Precautions & Warnings
- Discontinuation indications for certain events or conditions
- Blood pressure monitoring and treatment for hypertension
- Advising females of potential risk to a fetus
Use in Special Populations
- Pediatric use safety and effectiveness
- Safety and efficacy in pediatric patients
- Geriatric use and associated severe adverse events
Overdose Effects
- Highest tested dose on humans
- Associated side effects
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Refrigeration at 2-8°C
- Light sensitivity precautions
- Avoid freezing
- Keep out of reach of children